What pulmonologists think about the asthma–COPD overlap syndrome

Marc Miravitlles, Bernardino Alcázar, Francisco Javier Alvarez, Teresa Bazús, Myriam Calle, Ciro Casanova, Carolina Cisneros, Juan P. De-Torres, Luis M. Entrenas, Cristóbal Esteban, Patricia García-Sidro, Borja G. Cosio, Arturo Huerta, Milagros Iriberri, José Luis Izquierdo, Antolín López-Viña, José Luis López-Campos, Eva Martínez-Moragón, Luis Pérez de Llano, Miguel PerpiñáJosé Antonio Ros, José Serrano, Juan José Soler-Cataluña, Alfons Torrego, Isabel Urrutia, Vicente Plaza

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)


© 2015, Miravitlles et al. Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids.
Original languageEnglish
Pages (from-to)1321-1330
JournalInternational Journal of COPD
Publication statusPublished - 15 Jul 2015


  • ACOS
  • Asthma
  • COPD
  • Guidelines
  • Survey


Dive into the research topics of 'What pulmonologists think about the asthma–COPD overlap syndrome'. Together they form a unique fingerprint.

Cite this